Across TCGA pan-cancer cohorts, RALGAPA2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RALGAPA2 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RALGAPA2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RALGAPA2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where RALGAPA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.890	0.217	.001	17	view →
LSCC	OS	Tertile	II,III,IV	0.755	1.000	.028	3	view →
LUAD	OS	Tertile	All	1.000	0.977	.030	3	view →
CCRCC	OS	Median	All	0.712	0.921	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: RALGAPA2 tumor-vs-normal RNA expression · all RALGAPA2 data types